GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Gross Profit

Forty Seven (Forty Seven) Gross Profit : $15.68 Mil (TTM As of Dec. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Gross Profit?

Forty Seven's gross profit for the three months ended in Dec. 2019 was $0.00 Mil. Forty Seven's gross profit for the trailing twelve months (TTM) ended in Dec. 2019 was $15.68 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Forty Seven's gross profit for the three months ended in Dec. 2019 was $0.00 Mil. Forty Seven's Revenue for the three months ended in Dec. 2019 was $0.00 Mil. Therefore, Forty Seven's Gross Margin % for the quarter that ended in Dec. 2019 was N/A%.

Forty Seven had a gross margin of N/A% for the quarter that ended in Dec. 2019 => No sustainable competitive advantage


Forty Seven Gross Profit Historical Data

The historical data trend for Forty Seven's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Gross Profit Chart

Forty Seven Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Gross Profit
- - - 15.68

Forty Seven Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 15.68 -

Competitive Comparison of Forty Seven's Gross Profit

For the Biotechnology subindustry, Forty Seven's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forty Seven's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Gross Profit distribution charts can be found below:

* The bar in red indicates where Forty Seven's Gross Profit falls into.



Forty Seven Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Forty Seven's Gross Profit for the fiscal year that ended in Dec. 2019 is calculated as

Gross Profit (A: Dec. 2019 )=Revenue - Cost of Goods Sold
=15.678 - 0
=15.68

Forty Seven's Gross Profit for the quarter that ended in Dec. 2019 is calculated as

Gross Profit (Q: Dec. 2019 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.68 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Forty Seven's Gross Margin % for the quarter that ended in Dec. 2019 is calculated as

Gross Margin % (Q: Dec. 2019 )=Gross Profit (Q: Dec. 2019 ) / Revenue (Q: Dec. 2019 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Forty Seven  (NAS:FTSV) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Forty Seven had a gross margin of N/A% for the quarter that ended in Dec. 2019 => No sustainable competitive advantage


Forty Seven Gross Profit Related Terms

Thank you for viewing the detailed overview of Forty Seven's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154

Forty Seven (Forty Seven) Headlines

From GuruFocus

Forty Seven to Present at Upcoming Investor Conferences in March

By Marketwired Marketwired 02-25-2020